Carmot Therapeutics has entered into a collaboration and pharma license agreement with Amgen.
Carmot will apply its proprietary Chemotype Evolution to discover novel drug leads for two targets selected by Amgen.
Carmot and Amgen will work together to identify and optimize drug candidates, while Amgen will be solely responsible for their clinical development.
Carmot will receive an upfront payment, research funding, and pre-clinical and clinical milestone payments.
In addition, a royalty will be paid on commercial sales of products emerging from the collaboration.
View the full article at MarketWatch
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Amgen
Report: Partnering Deals and Alliances with Genzyme
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity